Chugai’s Hemlibra® Gains Positive CHMP Opinion in Severe Hemophilia A Without Inhibitors
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche has received notification that the EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for Hemlibra®, a treatment for hemophilia A created by Chugai, for routine prophylaxis of bleeding episodes in adults and children with severe hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. The CHMP has also adopted a positive opinion for additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors.
“We are thrilled that Hemlibra is expected to be approved shortly for people with severe hemophilia A without inhibitors in the Europe Union (EU). Also, I’m very pleased that people in the EU with hemophilia A will soon be offered multiple options of Hemlibra’s dosing interval regardless of their inhibitor expression,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Osamu Okuda. “Hemlibra is co-promoted by Chugai and Roche in Germany, France, and the United Kingdom, as is the case with the anti-rheumatic agent RoActemra®. We are committed to pursue our efforts in collaboration with Roche so that Hemlibra may further contribute to the treatment of hemophilia A.”
This positive opinion is based on results from two Phase III studies HAVEN 3 (NCT02847637) and HAVEN 4 (NCT03020160), conducted jointly with Roche and Genentech. HAVEN 3 study was conducted to evaluate the reduction of bleed rate of Hemlibra subcutaneous injection once a week and once every two weeks in people with hemophilia A (12 years of age or older) without inhibitors to factor VIII. HAVEN 4 study was conducted to evaluate efficacy, safety, and pharmacokinetics of Hemlibra subcutaneous injection every four weeks in people with hemophilia A (12 years of age or older), with and without inhibitors to factor VIII.
In Japan, Chugai obtained regulatory approval for Hemlibra from the Ministry of Health, Labour and Welfare in December 2018 for an additional indication of prophylactic treatment for people with hemophilia A without inhibitors to factor VIII, as well as for additional dosage and administration as a biweekly or every four-week treatment for people with hemophilia A with inhibitors to factor VIII.
Chugai’s HEMLIBRA® Receives Regulatory Approval from U.S. FDA
for Hemophilia A without Inhibitors
Press release issued on October 5, 2018
Chugai’s HEMLIBRA® Subcutaneous Injection Receives Approval
for Hemophilia A without Inhibitors and Extension of Dosing Interval --
HEMLIBRA is now available for Hemophilia A, regardless of inhibitor
Press release issued on December 21, 2018
About Severe Hemophilia A
People with severe hemophilia A is defined as the condition with less than 1 % of factor VIII levels. Hemophilia A affects around 320,000 people worldwide, 1,2 approximately 50-60% of whom are expected to have a severe form of the disorder3.
1) WFH. Guidelines for the management of haemophilia. 2012 [Internet;
cited 2018 July]. Available from:
http://www1.wfh.org/publications/files/pdf-1472.pdf. (as of February 1, 2019)
2) Berntorp E, Shapiro AD. Modern haemophilia care. The Lancet 2012; 370:1447-1456.
3) Marder VJ, et al. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and Wilkin.
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
Trademarks used or mentioned in this release are protected by law.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Appoints Katherine Weng General Manager for China22.8.2019 13:00:00 CEST | Press release
Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, announced the appointment of Katherine Weng as General Manager for Mary Kay (China) Co., Ltd. Based in Shanghai, Weng will report directly to Mary Kay’s Asia Pacific Region President, KK Chua. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190822005337/en/ Katherine Weng, General Manager for Mary Kay China. (Photo: Mary Kay Inc.) “Katherine’s tireless work ethic, strategic mindset, and ability to forge long-term relationships have enabled Mary Kay China to reach new heights,” says Chua. “She is passionate about our mission to enrich women’s lives. She understands our Independent Beauty Consultants’ needs and works hard to fulfill those needs to support their businesses. Within the company, she has successfully created a seamless link between sales, marketing and operations. We look forward to continued growth in China under her leadershi
Mattel® Launches Hot Wheels™ Infinite Loop Digital Racing Game, First-Ever Free-to-Play Game for the Hot Wheels® Brand22.8.2019 13:00:00 CEST | Press release
Mattel, Inc. (NASDAQ: MAT) today announced the launch of Hot Wheels™ Infinite Loop, a new digital racing game that brings the legendary Hot Wheels® catalog to mobile devices for the ultimate smash-and-crash speed competition. With an introduction timed to Gamescom, Europe’s leading trade fair for digital games culture held in Cologne, Germany, Hot Wheels Infinite Loop is available on the App Store for iPhone and iPad and allows fans to engage with the brand in an exciting new way. The first-ever Mattel-published, free-to-play game for the Hot Wheels franchise, Hot Wheels Infinite Loop reimagines the most famous Hot Wheels vehicles fans grew up with in a racing and car-collecting game for players ages 13 and above. Part of the fun of Hot Wheels has always been collecting coveted cars, and Hot Wheels Infinite Loop brings that concept back full circle. Players will compete in real-time against other racers from around the world to earn upgrades and collect the most legendary Hot Wheels ca
Registration for 2020 World Patient Safety, Science & Technology Summit Now Open22.8.2019 12:00:00 CEST | Press release
Registration for the Patient Safety Movement’s (PSMF) 2020 World Patient Safety, Science & Technology Summit is now open. Co-convened with the International Society for Quality in Health Care (ISQua), the American Society of Anesthesiologists and the European Society of Anaesthesiology, the 8th Annual Summit brings hospital leaders, medical and information technology innovators, patient advocates, policy makers and government officials together to discuss solutions to eliminate preventable patient deaths in hospitals around the world. “Preventable patient deaths due to medical error remains a significant challenge and we have a lot of work to do to get to our goal of zero deaths due to these errors,” said Dr. David Mayer, PSMF CEO. “At our Summit, important information and experiences will be shared to help us develop solutions to these challenges to eliminate errors and save lives. If you’re ready to join this movement, register to attend.” For more information about the 2020 World Pa
Veeva and MuleSoft Introduce MuleSoft Connector for Veeva Vault22.8.2019 11:03:00 CEST | Press release
Veeva Systems (NYSE:VEEV) today announced the MuleSoft Connector for Veeva Vault. MuleSoft, a Salesforce company, is working together with Veeva to make it faster and easier for life sciences companies to connect Veeva Vault applications with other enterprise systems. This latest product integration builds upon Veeva’s track record of innovation for joint Salesforce customers. “We’re excited to partner with Veeva to deliver new innovation to the life sciences industry,” said Brian Miller, senior vice president of business development, MuleSoft. “The MuleSoft ecosystem is driven by the expertise of successful partners like Veeva that help customers realize the benefits of the application network. We look forward to helping the life sciences industry better understand the opportunity of API-led connectivity to drive digital transformation within their organizations.” “We’re proud of our longstanding partnership with Salesforce and our ongoing collaboration to help move the industry forwa
c-LEcta: Successful Product Business in the First Half of 201922.8.2019 08:06:00 CEST | Press release
c-LEcta, a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully expanded its product business in the first half of 2019. Besides sales increases across the entire portfolio, the company was granted many new patents. While the patent portfolio still comprised 59 granted patents at the end of the first half of 2018, the Leipzig-based company now holds more than 80 patents. c-LEcta’s DENARASE®, which is used for the necessary removal of nucleic acids from biopharmaceutical products, performed particularly well. DENARASE® is the most efficient technology on the market for meeting the stringent regulatory requirements for biopharmaceutical products. Sales of this product increased by 164% year-on-year in the first half of 2019. The other products in c-LEcta’s portfolio also performed very well and contributed to the positive development of the product business. c-LEcta now markets its self-developed products in 25 co
MobileIron Named a Leader Again in the Second Gartner Magic Quadrant for Unified Endpoint Management Tools22.8.2019 07:00:00 CEST | Press release
MobileIron (NASDAQ:MOBL), the company that introduced the industry’s first mobile-centric, zero trust platform for the enterprise, today announced that it has been positioned as a Leader for the second consecutive year in the Gartner Magic Quadrant for Unified Endpoint Management Tools. The report evaluated 11 vendors based on completeness of vision and ability to execute. “To us, it’s an honor to be recognized once again as a Leader in Gartner’s Magic Quadrant for Unified Endpoint Management Tools,” said Simon Biddiscombe, CEO, MobileIron. “We have continued to innovate and expand upon our UEM platform to keep up with the demands of today’s digital businesses. Earlier this year, we introduced a revolutionary zero sign-on experience to eliminate passwords and make the world’s most ubiquitous product – the mobile device – your ID and secure access to the enterprise built on our leadership foundation in UEM. Mobile and cloud technologies have driven a dramatic change in organizations acr